Bioengineering Technology Market Report 2026

The bioengineering technology market size has grown rapidly in recent years. It will grow from $360.09 billion in 2025 to $404.05 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to early advancements in genetic engineering, rise of biomedical device innovation, increased demand for diagnostic precision, initial adoption of dna sequencing technologies, growth in bioprocessing research.

The bioengineering technology market size is expected to see rapid growth in the next few years. It will grow to $629.29 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to expansion of regenerative medicine, rising investment in nanobiotechnology, increasing demand for personalized healthcare, accelerated integration of bioinformatics analytics, growth of sustainable bioengineering solutions. Major trends in the forecast period include expansion of advanced gene manipulation techniques, increasing development of regenerative tissues and biomaterials, rising adoption of nanotechnology for biomedical applications, growth in biomechanical engineering solutions, accelerated innovation in bioinformatics platforms.

The increasing prevalence of chronic diseases is expected to drive the growth of the bioengineering technology market going forward. Chronic diseases are long-term health conditions characterized by their prolonged and persistent nature. Bioengineering technology is applied in the management and treatment of chronic diseases because it offers innovative solutions, improves patient outcomes, and enhances quality of life. For example, in April 2025, according to the NHS Confederation, a UK-based national association, it is estimated that by 2035, 17% of the UK population could be living with four or more chronic conditions. Therefore, the rising prevalence of chronic diseases is fueling the growth of the bioengineering technology market.

Major companies in the bioengineering technology market are emphasizing technological advancements such as viral vector manufacturing to improve the efficiency, scalability, and accuracy of gene and cell therapy production. Viral vector manufacturing involves the large-scale creation of engineered viruses that act as delivery vehicles for transporting therapeutic genes into target cells in gene and cell therapy applications. For example, in March 2025, Bharat Biotech, an India-based biotechnology firm, launched the country’s only fully integrated cell and gene therapy (CGT) facility to accelerate the development and production of advanced genetic treatments. This integration provides complete control over the manufacturing process, ensuring high quality while reducing costs, thereby increasing accessibility to advanced therapies. The facility is designed to promote innovation in personalized treatments for conditions such as cancer and genetic disorders, addressing unmet medical needs and strengthening India’s position in global healthcare. Its goal is to support the development and commercial introduction of affordable, transformative cell and gene therapies, ultimately enhancing patient outcomes and advancing India’s biotechnology sector.

In March 2023, Ginkgo Bioworks, a US-based horizontal platform for cell programming, acquired FGen AG for an undisclosed sum. This acquisition strengthens Ginkgo's position as a leader in the bioengineering field, providing it with a robust tool for strain development and optimization across various industries. FGen AG is a Switzerland-based bioengineering company.

Major companies operating in the bioengineering technology market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific, Abbott Laboratories, AstraZeneca plc, Medtronic plc, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Moderna Inc., Becton Dickinson (BD), Regeneron Pharmaceuticals, Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Agilent Technologies, Lonza Group Ltd., Intuitive Surgical, Illumina, Inc, Bio-Rad Laboratories, Ginkgo Bioworks, Verve Therapeutics, Inc., CRISPR Therapeutics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are affecting the bioengineering technology market by increasing the cost of imported laboratory equipment, advanced genetic engineering tools, and nanomaterials, which raises production and research expenses. Segments such as biotechnology, genetic engineering, and nano-biotechnology are most impacted, particularly in regions dependent on high-tech imports such as North America, Europe, and parts of Asia-Pacific. These tariffs also slow adoption of precision systems in healthcare and research institutions. Nonetheless, they encourage domestic manufacturing, stimulate regional innovation ecosystems, and support localized production of bioengineering inputs.

The bioengineering technology market research report is one of a series of new reports that provides bioengineering technology market statistics, including bioengineering technology industry global market size, regional shares, competitors with a bioengineering technology market share, detailed bioengineering technology market segments, market trends and opportunities, and any further data you may need to thrive in the bioengineering technology industry. This bioengineering technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bioengineering technology involves applying principles and techniques from engineering and the natural sciences to develop technologies and solutions for understanding, manipulating, and utilizing biological systems, particularly in the fields of medicine, biology, and healthcare.

The primary types of products in bioengineering technology include biomedical engineering, genetic engineering, biotechnology, tissue engineering, biomechanics engineering, biomaterials, nano-biotechnology, bioinformatics, and others. Biomedical engineering entails applying engineering principles and design concepts to medicine and biology for healthcare purposes. It encompasses various technologies such as nanobiotechnology, tissue engineering and regeneration, DNA sequencing, cell-based assays, and fermentation, and finds applications in health, food and agriculture, natural resources, and the environment.North America was the largest region in the bioengineering technology market in 2025. The regions covered in the bioengineering technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioengineering technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bioengineering technology market includes revenues earned by entities service such as medical diagnostic services, pharmaceutical services, personalized medicine services, engineering, and nanotechnology in medicine services, biological data analysis services, regenerative medicine services, and health information technology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The bioengineering technology market consists of sales of implantable medical devices, wearable health monitoring devices, biomedical imaging equipment, and diagnostic devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.